Für Sie gelesen: Tocilizumab (TCZ) Monotherapy is Superior to Adalimumab (ADA) Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis (RA): 24-Week Data from the Phase 4 ADACTA Trial

Baminger H

首页> 外文期刊>Journal fuer Mineralstoffwechsel und Muskuloskelettale Erkrankungen: Oesteologie - Rheumatologie - Orthopaedie >Für Sie gelesen: Tocilizumab (TCZ) Monotherapy is Superior to Adalimumab (ADA) Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis (RA): 24-Week Data from the Phase 4 ADACTA Trial

【24h】

Für Sie gelesen: Tocilizumab (TCZ) Monotherapy is Superior to Adalimumab (ADA) Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis (RA): 24-Week Data from the Phase 4 ADACTA Trial

机译：FürSie gelesen：在减少类风湿关节炎（RA）患者的疾病活动方面，Tocilizumab（TCZ）单一疗法优于Adalimumab（ADA）单一疗法：ADACTA 4期试验的24周数据

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal fuer Mineralstoffwechsel und Muskuloskelettale Erkrankungen: Oesteologie - Rheumatologie - Orthopaedie》 |2012年第3期|共页
作者
Baminger H;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类生物工程学（生物技术）;
关键词

相似文献

外文文献
中文文献
专利

1. Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis [J] . Jennie H. Best, Steven C. Vlad, Jinglan Pei Rheumatology and Therapy . 2020,第1期

机译：4种临床终点与黄铜单药物对类风湿性关节炎患者的头脑中的4临床单药治疗的每种临床终点的比较成本与黄铜对单体化双盲优势试验（ADACTA）
2. Erratum: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial (The Lancet (2013) 381 (1531-1550)) [J] . The Lancet . 2013,第9877期

机译：勘误：托珠单抗单药与阿达木单抗单药治疗类风湿关节炎（ADACTA）：一项随机，双盲，对照4期临床试验（《柳叶刀》（2013）381（1531-1550））
3. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase 4 trial [J] . GabayC., EmeryP., VanVollenhovenR., The Lancet . 2013,第9877期

机译：托珠单抗单药与阿达木单抗单药治疗类风湿关节炎（ADACTA）：一项随机，双盲，对照的4期临床试验
4. Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis [O] . Jennie H. Best, Steven C. Vlad, Jinglan Pei 2020

机译：类风湿关节炎患者头对头随机双盲优越性试验（ADACTA）中4种临床终点采用Tocilizumab单药治疗与Adalimumab单药治疗的每项治疗反应的比较费用
5. Comparative Cost Per Response for four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-To-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis [O] . JH Best, J Pei 2018

机译：对类黄芩素治疗的四种临床结果对幼王随机双盲优越性试验（Adacta）的四种临床结果进行了对比较成本

Für Sie gelesen: Tocilizumab (TCZ) Monotherapy is Superior to Adalimumab (ADA) Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis (RA): 24-Week Data from the Phase 4 ADACTA Trial

著录项

相似文献

相关主题

期刊订阅